CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $28,000 | -98.3% | 623 | -98.4% | 0.00% | -100.0% |
| Q4 2022 | $1,624,000 | -97.0% | 39,941 | -95.2% | 0.00% | -97.0% |
| Q3 2022 | $54,791,000 | +901.5% | 837,435 | +830.3% | 0.07% | +1016.7% |
| Q2 2022 | $5,471,000 | +4348.0% | 90,022 | +4476.6% | 0.01% | – |
| Q1 2022 | $123,000 | -17.4% | 1,967 | 0.0% | 0.00% | – |
| Q4 2021 | $149,000 | -99.9% | 1,967 | -99.8% | 0.00% | -100.0% |
| Q3 2021 | $110,239,000 | -41.3% | 984,890 | -15.1% | 0.09% | -39.0% |
| Q2 2021 | $187,755,000 | +36286.6% | 1,159,767 | +27285.3% | 0.15% | +15300.0% |
| Q1 2021 | $516,000 | -97.9% | 4,235 | -97.4% | 0.00% | -97.2% |
| Q4 2020 | $24,549,000 | +337.8% | 160,335 | +139.1% | 0.04% | +300.0% |
| Q3 2020 | $5,607,000 | -20.0% | 67,044 | -29.7% | 0.01% | -25.0% |
| Q2 2020 | $7,007,000 | +49950.0% | 95,340 | +15790.0% | 0.01% | – |
| Q4 2017 | $14,000 | – | 600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |